Texas Biotech (TXB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (802)	5/14/2001 12:00:35 PM
From: keokalani'nui	Read Replies (1) of 834

From Message 15795290 . I'll post the abstract later. Thanks Peter. >>According to Joel B. Nelson, MD, from the University of Pittsburgh, for the first time, a new agent has been shown to slow the progression of bone metastasis from prostate cancer. Dr. Nelson will report results from two multinational, randomized, double-blind, placebo-controlled trials to evaluate the effects on bone metabolism of the endothelin-A receptor antagonist atrasentan (ABT-627). The design of the trial was developed from earlier findings from Dr. Nelson’s laboratory showing that endothelin-1 (ET-1), a prostate protein that enhances osteoblastic activity and inhibits osteoclastic activity, is present in increased levels in men with advanced prostate cancer, and that blocking ET-1 can reduce osteoblastic bone formation. Dr. Nelson will provide evidence that oral atrasentan succeeds in reducing skeletal remodeling activity in men with advanced, hormone-refractory prostate cancer and is capable of inhibiting the progression of skeletal metastases.<< Wilder

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next